ANA as an entry criterion for the classification of SLE.
Antinuclear antibody
Classification criteria
HEp2 immunofluorescence assay
Solid phase assays
Systemic lupus erythematosus
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
20
06
2019
accepted:
25
06
2019
pubmed:
23
10
2019
medline:
6
2
2020
entrez:
23
10
2019
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease with highly variable clinical and immunological manifestations. In the classification of patients with this condition, the presence of an antinuclear antibody (ANA) is an important element, with new criteria from the American College of Rheumatology and European League against Rheumatism positioning ANA positivity by an immunofluorescence assay on HEp2-cells (HEp2-IFA) or by an equivalent solid phase assay as the entry criterion. This positioning is based on assumptions about the frequency of ANA positivity in SLE as well as the reliability of the assays. Studies indicate that these assumptions are still a matter of uncertainty since both types of assay show considerable variability and patients with SLE may display negative results in ANA testing. These findings suggest caution in positioning ANA positivity as an entry criterion for classification and point to the value of alternative serological approaches for ANA determinations.
Identifiants
pubmed: 31639513
pii: S1568-9972(19)30207-1
doi: 10.1016/j.autrev.2019.102400
pii:
doi:
Substances chimiques
Antibodies, Antinuclear
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102400Subventions
Organisme : BLRD VA
ID : I01 BX003772
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.